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A detailed study of the alterations in the serum protein fractions following commen-
cement of effective anti-tuberculosis treatment was undertaken in 511 patients with
pulmonary tuberculosis. The concentration of serum albumin was 20-30 per
cent higher (P<0.001) and that of 1, a2 and g -globulins significantly lower at
the end of treatment than on admission (P<0.01), the magnitude of decrease being
7-17 per cent for g -globulin, 19-30 per cent fora1- globulin and 35-38 per cent for
a2- globulin. In all, 481 patients had a favourable response to treatment, 46 of
whom had a bacteriological relapse within 18 months of stopping treatment. The
likelihood of a relapse was found to be greater with higher a2 - lobulin concentra-
tions at the end of treatment, the proportions of patients who relapsed being 3, 9,
13 and 15 per cent with a2 -globulin concentrations of < 0.40, 0.40-0.59, 0.60-0.79
and >  0.80 g/dl (P=0.02).
It has been well established that in
chronic infectious diseases like tuberculo-
sis, the albumin content of serum proteins
shows a decrease while the globulin content
shows an increase leading to low albumin
to globulin (A/G) and albumin to a2 -
globulin (A/ a2) ratios
1,2. An investigation
was undertaken to study the alterations
in serum protein profile following com-
mencement of effective anti-tuberculosis
treatment, and to examine whether these
changes are associated with immediate
response to treatment and a subsequent
likelihood of relapse.
Material & Methods
The investigations were undertaken in
511 patients with sputum-positive pulmo-
nary tuberculosis;of these, 422 had
organisms initially sensitive to isoniazid
and streptomycin, and 89 resistant either
to o e or both the drugs. These patients
were allocated at random to one of the
following regimens :
R3: Rifampicin (12 mg/kg body weight)
plus streptomycin (0.75 g) plus isoniazid
(400 mg) plus pyrazinamide (35 mg/kg)
daily for 3 months.
R5: The same as R3 plus a twice-weekly
phase of 2 months with streptomycin
(0.75 g), isoniazid (15 mg/kg) and pyra-
zinamide (70 mg/kg).
Z5: The same as R5, but without rifam-
picin.
Blood samples were obtained at 0 and
3 months from patients admitted to the
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R3 regimen, and at 0, 3 and 5 months
from those admitted to the R5 and 25
regimens and also from 18 healthy volun-
teers. The total serum protein content was
determined by the Biuret method3. T e
different serum protein fractions were
separated electrophoretically4 at a pH
of 8.6 (0.06M barbitone-sodium barbitone
buffer, µ=0.05) using Whatman No. 3
filter paper at a constant voltage of 210 V
for 5) h. The proteins were stained with
methanolic bromophenol blue, and the
different fractions were eluted with 0.01 M
sodium hydroxide. The extinction was
recorded at 540 nm, and the concentrations
of the individual fractions were calculated
on the basis of these values and the total
protein content of each sample.
Counts of viable tubercle bacilli
isolated from sputa of patients were set
up as described earlier5, and the classi-
fication of the radiographic extent of
tuberculous disease was undertaken as
detailed earlier6.
A patient was deemed to have had an
unfavourable bacteriological response if
he had one or more of 3 cultures positive
for Mycobacterium tuberculosis at each of
the last 2 months of treatment, irrespective
of the amount of growth. The response
was also considered unfavourable in pa-
tients who had chemotherapy continued
beyond the prescribed duration on account
of clinical or radiographic deterioration,
and in those who died of tuberculosis. A
bacteriological relapse has been defined as
the occurrence of 2 or more positive
cultures for M. tuberculosis (of a total of
6 cultures) at different months in any 3
consecutive monthly examinations, irres-
pective of the amount of growth. Treat-
ment was started only if at least one of the
cultures had a growth of 20 colonies or
more in the presence of at least one posi-
tive smear, and also in those who intermit-
tently produced positive cultures (of any
grade of growth) over several months.
Results
The mean values of the serum protein
fractions and the A/G and A/ a2 ratios
in patients with initially drug-sensitive
and drug-resistant organisms before start
of treatment, and in healthy volunteers
are presented in Table I. The serum albu-
min content was lower (about 40%),
while the concentrations of all the globulin
fractions were higher, ranging from about
20 per cent for b -globulin to about 200
per cent for a1 -globulin, in the tuberculous
patients than in the healthy volunteers
leading to appreciably lower(about
60-65%) A/G and A/ a2 ratios in the former.
The mean values of all the protein fractions
and the ratios were similar in patients
with initially drug-sensitive and drug-
resistant organisms.
The association between the concentra-
tions of a2 or g -globulin, the A/G or
A/ a2 ratios and the disease status on
admission, as measured by the radiogra-
phic extent of tuberculous disease and
the log viable count of tubercle bacilli
isolated from the sputa of the patients was
examined (Table II). There was an increa-
sing trend in the mean concentrations of
a2 and g -globulins and a corresponding
decreasing trend in the A/G and A/ a2
ratios with an increase in the severity of
disease as measured by either the radio-
graphic extent of the disease or the count
of viable tubercle bacilli (P<0.01).
Changes in the protein fractions during
treatment are presented in Table III; the
findings in patients with initially drug-
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Table I. Serum protein concentrations in patients with pulmonary tuberculosis and in healthy volunteers
(Data are mean±SD)
Serum protein fraction
(g/dl)
Drug-sensitive
patients (422)
Drug-resistant
patients (89)
Healthy volunteers
(18)
Total protein 6.82 ± 0.59
Albumin 2.71 ± 0.56
a1 -globulin 0.33 ± 0.11
a2 -globulin 0.86 ± 0.20
b -globulin 0.67 ± 0.14
g -globulin 2.24 ± 0.53
A/G ratio 0.69 ± 0.25
A/ a2 ratio 3.52 ± 2.38
Figures in ‘parentheses are numbers studied
6.83 ± 0.56 6.64 ± 0.44
2.78 ± 0.54 4.34 ± 0.35
0.32 ± 0.11 0.11 ± 0.04
0.87 ± 0.22 0.48 ± 0.10
0.66 ± 0.14 0.55 ± 0.04
2.20 ± 0.53 1.16 ± 0.27
0.72 ± 0.26 1.93 ± 0.38
3.53 ± 1.75 9.49 ± 2.20
Table II. Association between disease status on admission and serum protein fractions and ratios
(Data are mean values)
Slight 47 0.73 2.02 1.00 5.36 0 20 0.67 1.91 1.04 6.42
Limited 118 0.88 2.09 0.77 3.62 1- 53 0.80 2.19 0.78 3.99
Moderate 181 0.90 2.36 0.74 3.68 3- 162 0.84 2.21 0.73 3.58
Extensive 161 0.90 2.40 0.63 3.06 5- 217 0.91 2.28 0.67 3.11
Gross 4 0.89 2.39 0.60 2.83 7- 53 0.93 2.26 0.60 2.82
*Based on 511 patients: **Based on 505 patients only
sensitive and drug-resistant organisms have
been amalgamated as these were similar.
There was little change with treatment in
the total protein content. However, there
was a 20-30 per cent increase in the serum
albumin content during treatment
(P<0.001), and significant decreases
(P<0.01) in all the globulin fractions
excepting b -globulin in the 3 groups, the
magnitude of decrease being 6-8 per cent
for b -globulin, 7-17 percent for g -globulin,
19-30 per cent for a1 -globulin and 35-38
p  cent for a2 -globulin. Consequently, the
A/G and A/ a2 ratios were appreciably
higher (41-66 and 87-114%, respectively)
at the end of treatment in all the groups
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Table III. Changes in the serum protein concentrations during treatment
(Data are mean ± SD)
Protein fraction
(g/dl)
R3 (167) R5 (179)
Months of treatment
Z5 (145)
0 3 0 3 5 0 3 5
Total protein
Albumin
a1 -globulin
a2 -globulin
b -globulin
g -globulin
A/G ratio
A/ a2 ratio
6.93 6.91 6.77 6.78
± 0.52 ± 0.54 ± 0.62 ± 0.55
2.79
± 0.53
0.32
± 0.10
0.86
± 0.18
0.67
± 0.14
2.29
± 0.53
3.35 2.74
± 0.46 ± 0.54
0.26 0.33
± 0.12 ± 0.12
0.56 0.86
± 0.14 ± 0.22
0.62 0.66
± 0.16 ± 0.15
2.12 2.18
± 0.50 ± 0.52
3.35
± 0.51
0.27
± 0.15
0.55
± 0.15
0.59
± 0.15
2.01
± 0.48
0.70 0.99
± 0.25 ± 0.29
3.51 6.57
± 1.57 ± 2.44
0.72 1.04
± 0.26 ± 0.34
3.56 6.68
± 2.16 ± 2.69
6.70
± 0.52
3.51
± 0.52
0.23
± 0.11
0.53
± 0.15
0.61
± 0.15
1.81
± 0.46
1.17
± 0.38
7.39
± 2.85
6.78
± 0.56
7.03
± 0.52
2.68
± 0.58
0.34
± 0.11
0.86
± 0.21
0.66
± 0.13
2.24
± 0.53
3.48
± 0.51
0.25
± 0.11
0.58
± 0.15
0.63
± 0.15
2.08
± 0.50
0.68 1.04
± 0.26 ± 0.32
3.34 6.47
± 1.54 ± 2.35
6.84
± 0.51
3.51
± 0.55
0.26
± 0.31
0.54
± 0.13
0.62
± 0.15
1.91
± 0.48
1.13
± 0.37
7.16
± 2.70
Figures in parentheses indicate number studied.*Twenty patients (7 R3, 5 R5 and 8 Z5) have been
excluded due to non-availability of data at all the specified time-points
(P<0.001). No association was observed
between the magnitude of change with
treatment in the protein concentrations
or the A/G or A/ a2 ratio and the
disease status on admission (data not
presented).
Of the patients with initially drug
sensitive organisms, all but one (R3) had a
favourable response; however, a bacterio-
logical relapse requiring treatment occurr-
ed in 21 (15%) of 136 R3, 4(3%) of 146 R5,
and 15 (12%) of 129 Z5 patients within 18
months after stopping treatment. Among
patients with initially drug-resistant orga-
nism , response was unfavourable in 1 of
30 R3, 3 of 33 R5 and 5 of 16 Z5 patients ;
of the remaining 70 patients, 6 (3 R3, 1 R5
and 2 Z5) had a bacteriological relapse
within 18 months after stopping treatment.
Since it appears that of all protein fractions
examined, only the a2 and the g -globulin
fractions are likely to be of any importance,
further comparisons were made only for
these two fractions and the A/G and the
A/ a2 ratios.
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The mean a2 and g -globulin concentra-
tions at the end of treatment in the 10
patients (9 of whom had initially drug-
resistant organisms) who had an unfavour-
able response at the end of thescheduled
period of treatment were 0.61 and 242
g/dl, values higher than in those who had a
favourable response (0.54 and 1.94 g/dl,
respectively). The mean A/G and A/ a2
ratios in the former group (0.86 and 5.85,
respectively) were lower than those in the
latter group (1.10 and 7.07 respectively).
Comparison of the values in patients
who had a bacteriological relapse with
those who did not (Table IV), showed that
those who relapsed on the 2 rifampicin
regimens had higher a2 -globulin (P<0.01)
and g -globulin (P > 0.2) concentrations, and
lower A/G (P = 0.04) and A/ a2 (P< 0.01)
ratios at the end of treatment than those
who did not have a bacteriological relapse.
For patients in the Z5 regimen, these
values were similar in patients who relapsed
and in those who did not.Amalgamating
the results of patients from all regimens
at the end of treatment, it was observed
that the mean concentrations of both the
globulin fractions ( a2 and g ) were higher,
and the mean ratios (A/G and A/ a2
were lower in patients who relapsed than
in those who did not. Thus, the mean
values for the a2 and g -globulin concen-
trations, and the A/G and A/ a2 ratios in
patients who had a bacteriological relapse
were 0.58 and 2.02 g/d1 and 1.04 and 6.28
resp ctively; the corresponding values in
patients who did not relapse, were 0.53
and 1.93 g/d1 and 1.11 and 7.15 respectively.
The differences attained statistical signi-
ficance (P<0.04) only with the a2 -globulin
concentration and the A/ a2 ratio. The
mean at-globulin concentrations at the
end of treatment in patients who relapsed
and in those who did not (not tabulated)
were 0.28 and 0.25 g/dl, respectively ; the
differ nce was not significant (P>0.2).
The likelihood of a relapse was found
to be greater with higher a2 -globulin con-
centrations at the end of treatment, the
proportions of patients who relapsed
Table IV. Serum protein concentration at the end of chemotherapy in patients with bacteriological
relapse
(Data are mean ± SD)
Regimen Group No. of A/G A / a2
patients
R3 + R5 Relapse 29 0.61 ± 0.12 2.03 ± 0.50 0.95 ± 0.35 5.71 ± 1.88
No relapse 312 0.53 ± 0.15 1.94 ± 0.50 1.10 ± 0.35 7.13 ± 2.71
Z5 Relapse 17 0.53 ± 0.14 2.01 ± 0.54 1.18 ± 0.50 7.24 ± 2.78
No relapse 123 0.54 ± 0.13 1.89 ± 0.46 1.14 ± 0.35 7.20 ± 2.71
All Relapse 46 0.58 ± 0.13 2.02 ± 0.51 1.04 ± 0.42 6.28 ± 2.35
regimens No relapse 435 0.53 ± 0..14 1.93 ± 0.49 1.11 ± 0.35 7.15 ± 2.71
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being 3, 9, 13 and 15 per cent with a2-
globulin concentrations of <0.40, 0.40-
0.59, 0.60-0.79 and > 0.80 g/dl, respectively,
a significant trend (P=0.02). Such a trend
was not observed with the other globulin
fractions.
Of the 46 patients who relapsed within
18 months after stopping treatment,
32 had an early relapse (within 6 months),
and the remaining had a late relapse
(7-18 months). The mean a2 -globulin con-
centrations in the early and late relapses
were 0.61 and 0.53 g/dl, respectively
(P=0.06); the mean A/ a2 ratios in the
2 groups were 5.99 and 6.93, respectively
(P>0.2). The mean r-globulin concen-
trations and A/G ratios (results not
presented) were similar in the 2 groups.
Discussion
The study of serum protein profile
before and during treatment with short
course regimens was undertaken primarily
to identify factors of prognostic significance
in patients with pulmonary tuberculosis.
Weak associations, though statistically
significant, were observed between the
extent of tuberculous disease on admission
and the concentrations of a2 and g -glo-
bulins and the A/G and A/ a2 ratios.
During treatment, the mean decrease in
the concentration of a2 -globulin was more
pronounced than that of the other globu-
lins, and the increase in the A/ a2 ratio
was substantially higher than that of the
A/G ratio. Similar observations were
made by Gilliland and others1 who sug-
gested that the A/ a2 ratio could be emplo-
yed to assess the activity of the disease
and to monitor the progress of the patient
during chemotherapy.
Almost all the patients with initially
drug sensitive organisms, and a substantial
proportion of those with organisms initially
resistant tostreptomycin or isoniazid
or both had a bacteriologically favour-
able response at the end of the scheduled
periods of chemotherapy with effective
short-course regimens containing rifam-
picin and pyrazinamide in addition to
isoniazid and streptomycin; however, bac-
teriological relapses requiring treatment
occurred in varying proportions of
pati nts with the 3 regimens investigated
after stopping treatment. Results reported
in this paper suggest that of all the protein
fractions examined, the a2 -globulin fra-
tion is probably of greater prognostic
significance than the other fractions.
The classification of the proportions of
relapses according to the a2 -globulin con-
centrations at the end of treatment showed
an increase with increasing concentrations;
it was, however, not possible to determine
the level of the concentration at which
the outcome of a relapse could be pre-
dicted. The concentration of this fraction
is known to be elevated in conditions
where tissue necrotic changes are known
to occur. The observation that the 2 -
globulin concentration was higher in
pat e ts who relapsed than in those who
did not suggests that active tissue des-
truction is possibly still in progress in
th former. The mean concentration of
this protein fraction was also slightly
higher in patients who relapsed early
(within 6 months after stopping treatment)
than in those who had a later relapse
(7-18 months) suggesting a greater degree
of active tissue destruction in the early
relapses.
The a2 -globulin fraction consists of
a number of proteins with similar electro-
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phoretic mobilities, some of which like
ceruloplasmin are acute phase proteins.
The concentrations of these proteins are
known to be increased in response to
inflammatory reactions involving tissue
damage and infection7 The elevated con-
centrations of the a2 -fraction in tubercu-
lous patients before start of treatment,
and the slightly higher concentrations in
patients who had an unfavourable response
or in those who had a bacteriological
relapse after stopping treatment might
be due to the higher concentrations of
these acute phase proteins. However, no
firm conclusions on the possible signi-
ficance of the findings reported here can
be drawn until data are available on the
a2 -globulin and the constituent acute
phase protein concentrations at time-points
between the end of treatment and the
occurrence of relapse.
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